IONS: Licenses Zilganersen
Ionis Pharmaceuticals licenses zilganersen to Recordati for $30M upfront payment for all countries outside the US
S. assuming FDA approval
Ionis Pharmaceuticals licenses zilganersen to Recordati for $30M upfront payment for all countries outside the US
S. assuming FDA approval